| Drug Name | ***0022 |
| Description |
An oral small molecule CSF1R inhibitor is in early clinical development for the oral treatment of solid tumors. |
| Target | Colony-Stimulating Factor 1 Receptor (CSF-1R) |
| Drug Modality | Small Molecule |
| Indication | Solid Tumor |
| Product Category | Angiogenesis Inhibitors |
| Mechanism of Action | Inhibiting Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R) to Suppress Tumor Angiogenesis |
| Status | Phase I |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |